Atrial remodelling and dysfunction in hypertrophic cardiomyopathy: prognostic role and therapeutic target
IntroductionHypertrophic cardiomyopathy (HCM) is a common genetic cardiac disease marked by abnormal ventricular hypertrophy. Recent studies have highlighted that left atrial (LA) remodelling—including dilation, fibrosis, and functional impairment—plays a key role in disease progression and prognosi...
Saved in:
| Main Authors: | Chiara Piazzai, Alessio Petrone, Andrea Stefanini, Flavio D’Ascenzi, Iacopo Olivotto, Matteo Cameli |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1620313/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Beneficial Atrial Septal Defect Shunt in Hypertrophic Cardiomyopathy—When Closure Is Not the Answer
by: Mohammad Alnoor, MD, et al.
Published: (2024-10-01) -
Cardiovascular Hospitalizations Burden Following Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy
by: Ahmed Altibi, et al.
Published: (2025-07-01) -
Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy
by: Bryton J. Davis, et al.
Published: (2025-03-01) -
Predictive model development for left atrial remodeling in hypertrophic cardiomyopathy
by: Bowen Zhang, et al.
Published: (2025-04-01) -
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCM
by: Caroline J. Coats, et al.
Published: (2024-08-01)